Anteris Technologies Global (AVR) Stock Overview
A structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AVR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Anteris Technologies Global Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.85 |
| 52 Week High | AU$15.94 |
| 52 Week Low | AU$4.26 |
| Beta | 0.30 |
| 1 Month Change | -20.75% |
| 3 Month Change | -35.33% |
| 1 Year Change | -69.01% |
| 3 Year Change | -82.14% |
| 5 Year Change | 47.87% |
| Change since IPO | -93.62% |
Recent News & Updates
Recent updates
Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why
May 22
Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)
Jul 08Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now
May 07Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?
Feb 21
Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling
Dec 10Shareholder Returns
| AVR | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -6.4% | 2.4% | 0.9% |
| 1Y | -69.0% | -6.0% | 10.1% |
Return vs Industry: AVR underperformed the Australian Medical Equipment industry which returned -6% over the past year.
Return vs Market: AVR underperformed the Australian Market which returned 10.1% over the past year.
Price Volatility
| AVR volatility | |
|---|---|
| AVR Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 10.6% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 18.5% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: AVR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AVR's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 136 | Wayne Paterson | anteristech.com |
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
Anteris Technologies Global Corp. Fundamentals Summary
| AVR fundamental statistics | |
|---|---|
| Market cap | AU$174.90m |
| Earnings (TTM) | -AU$124.61m |
| Revenue (TTM) | AU$3.80m |
Is AVR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVR income statement (TTM) | |
|---|---|
| Revenue | US$2.49m |
| Cost of Revenue | US$1.17m |
| Gross Profit | US$1.32m |
| Other Expenses | US$83.13m |
| Earnings | -US$81.80m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 53.03% |
| Net Profit Margin | -3,281.39% |
| Debt/Equity Ratio | 1.7% |
How did AVR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/25 02:01 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anteris Technologies Global Corp. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| John Hester | Bell Potter |
| Ross Osborn | Cantor Fitzgerald & Co. |